UTHR - United Therapeutics Corp
IEX Last Trade
363.32
3.100 0.853%
Share volume: 448,117
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$360.22
3.10
0.86%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-02 | 2023-02-22 | 2023-05-03 | 2023-08-02 | 2023-11-01 | 2024-02-21 | 2024-05-01 | 2024-07-31 | |
| Assets | |||||||||
| Total Assets | 5.782 B | 6.045 B | 6.346 B | 6.681 B | 7.024 B | 7.167 B | 6.495 B | 6.723 B | |
| Current Assets | 3.056 B | 3.380 B | 3.193 B | 3.213 B | 3.459 B | 3.551 B | 3.249 B | 3.620 B | |
| Inventories | 91.000 M | 102.000 M | 102.500 M | 103.300 M | 104.300 M | 111.800 M | 120.200 M | 136.500 M | |
| Other Current Assets | 118.100 M | 219.200 M | 92.600 M | 158.400 M | 220.500 M | 166.200 M | 113.400 M | 220.800 M | |
| Short Term Investments | 118.100 M | 219.200 M | 92.600 M | 158.400 M | 220.500 M | 166.200 M | 113.400 M | 220.800 M | |
| Total Receivables | 231.700 M | 220.400 M | 134.500 M | 272.700 M | 258.600 M | 278.900 M | 307.300 M | 290.700 M | |
| Current Cash | 2.616 B | 2.839 B | 2.863 B | 2.679 B | 2.876 B | 2.994 B | 2.708 B | 2.972 B | |
| Total Non-current Assets | 2.725 B | 2.664 B | 3.153 B | 3.468 B | 3.565 B | 3.616 B | 3.247 B | 3.104 B | |
| Property Plant Equipment | 840.800 M | 861.500 M | 896.500 M | 938.900 M | 992.200 M | 1.045 B | 1.074 B | 1.095 B | |
| Other Assets | 114.800 M | 114.300 M | 124.500 M | 135.300 M | 141.700 M | 151.800 M | 169.100 M | 167.900 M | |
| Intangible Assets | 44.500 M | 44.500 M | 44.500 M | 44.500 M | 44.400 M | 114.200 M | 115.400 M | 115.200 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 5.782 B | 6.045 B | 6.346 B | 6.681 B | 7.024 B | 7.167 B | 6.495 B | 6.723 B | |
| Total liabilities | 1.219 B | 1.248 B | 1.223 B | 1.270 B | 1.312 B | 1.182 B | 1.157 B | 1.026 B | |
| Total current liabilities | 315.900 M | 343.200 M | 324.600 M | 370.300 M | 744.100 M | 804.400 M | 860.600 M | 832.300 M | |
| Accounts Payable | 0.000 | 4.100 M | 0.000 | 0.000 | 0.000 | 5.600 M | 0.000 | 0.000 | |
| Other liabilities | 103.500 M | 104.600 M | 98.200 M | 100.000 M | 67.400 M | 77.800 M | 96.500 M | 93.700 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 300.000 M | 400.000 M | 400.000 M | 400.000 M | |
| Long term debt | 800.000 M | 800.000 M | 800.000 M | 800.000 M | 500.000 M | 300.000 M | 200.000 M | 100.000 M | |
| Other liabilities | 103.500 M | 104.600 M | 98.200 M | 100.000 M | 67.400 M | 77.800 M | 96.500 M | 93.700 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 4.562 B | 4.797 B | 5.123 B | 5.411 B | 5.712 B | 5.985 B | 5.338 B | 5.697 B | |
| Common stock | 45.500 M | 45.900 M | 46.300 M | 46.900 M | 46.900 M | 47.100 M | 47.000 M | 44.400 M | |
| Retained earnings | 4.910 B | 5.042 B | 5.283 B | 5.542 B | 5.810 B | 6.027 B | 6.334 B | 6.612 B |